SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc. (Amendment)

Recent Analyst Ratings for $IOVA

$IOVA Insider Trading

$IOVA Press Releases

$IOVA Financials

$IOVA Large Ownership Changes

$IOVA SEC Filings

$IOVA Insider Purchases

$IOVA Market Insights

$IOVA Leadership Updates

$IOVA Analyst Ratings

$IOVA FDA approvals

Recent Analyst Ratings for
$IOVA

$IOVA
Insider Trading

$IOVA
Press Releases

$IOVA
Financials

$IOVA
Large Ownership Changes

$IOVA
SEC Filings

$IOVA
Insider Purchases

$IOVA
Market Insights

$IOVA
Leadership Updates

$IOVA
Analyst Ratings

$IOVA
FDA approvals

Chat with this insight

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Maynard Ryan D exercised 50,000 shares at a strike of $7.45 and sold $503,000 worth of shares (50,000 units at $10.06) (SEC Form 4)

Interim CEO & General Counsel Vogt Frederick G covered exercise/tax liability with 8,851 shares and converted options into 20,834 shares, increasing direct ownership by 6% to 204,245 units (SEC Form 4)

Chief Medical Officer Graf Finckenstein Friedrich converted options into 2,813 shares and covered exercise/tax liability with 1,428 shares, increasing direct ownership by 2% to 60,727 units (SEC Form 4)

Fastest customizable press release news feed in the world

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024

Live finance-specific insights

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

SEC Form SC 13D/A filed by Iovance Biotherapeutics Inc. (Amendment)

Iovance Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

SEC Form 144 filed by Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Live Market Insights

Mcpeak Merrill A bought $2,287,500 worth of shares (250,000 units at $9.15), increasing direct ownership by 356% to 320,150 units (SEC Form 4)

Dukes Iain D. bought $292,800 worth of shares (32,000 units at $9.15), increasing direct ownership by 145% to 54,000 units (SEC Form 4)

Rothbaum Wayne P. bought $45,750,000 worth of shares (5,000,000 units at $9.15) (SEC Form 4)

10 Health Care Stocks Whale Activity In Today's Session

How Is The Market Feeling About Iovance Biotherapeutics?

Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday

Live Leadership Updates

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors

BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

UBS initiated coverage on Iovance Biotherapeutics with a new price target

Iovance Biotherapeutics downgraded by Piper Sandler with a new price target

Goldman initiated coverage on Iovance Biotherapeutics with a new price target

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

2/9/24 5:40:28 PM ET

$IOVA

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $IOVA alert in real time by email

SC 13G/A 1 d749949dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Iovance Biotherapeutics, Inc.

(Name of Issuer)

common stock, par value $0.000041666

(Title of Class of Securities)

462260 10 0

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☒

Rule 13d-1(c)

☐

Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

Item 1

(a) Name of Issuer:

Iovance Biotherapeutics, Inc. (the “Issuer”)

Item 1

(b) Address of Issuer’s Principal Executive Offices:

999 Skyway Road, Suite 150, San Carlos, California 94070

Item 2

(a) Name of Person Filing:

This Statement is being filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

(i)

MHR Capital Partners Master Account LP (“Master Account”);

(ii)

MHR Advisors LLC (“Advisors”);

(iii)

MHRC LLC (“MHRC”);

(iv)

MHR Fund Management LLC (“Fund Management”);

(v)

MHR Holdings LLC (“Holdings”); and

(vi)

Mark H. Rachesky, M.D. (“Dr. Rachesky”).

This statement relates to securities held for the accounts of each of Master Account, a limited partnership organized in Anguilla, British West Indies, MHR Capital Partners (100) LP, a Delaware limited partnership (“Capital Partners (100)”) and Dr. Rachesky. Advisors is the general partner of each of Master Account and Capital Partners (100), and, in such capacity, may be deemed to beneficially own the shares of common stock of the Issuer, par value $.0.000041666 (the “Common Stock”) held for the accounts of each of Master Account and Capital Partners (100). MHRC, a Delaware limited liability company, is the managing member of Advisors and, in such capacity, may be deemed to beneficially own the Common Stock beneficially owned by each of Master Account and Capital Partners (100). Fund Management is a Delaware limited liability company that is an affiliate of and has an investment management agreement with Master Account and Capital Partners (100), and other affiliated entities, pursuant to which it has the power to vote or direct the vote and to dispose or to direct the disposition of the securities reported herein and, accordingly, Fund Management may be deemed to beneficially own the shares of Common Stock reported herein which are held for the account of each of Master Account and Capital Partners (100). Holdings, a Delaware limited liability company, is the managing member of Fund Management and, in such capacity, may be deemed to beneficially own the Common Stock beneficially owned by each of Master Account and Capital Partners (100). Dr. Rachesky is the managing member of MHRC and Holdings and, in such capacity, may be deemed to beneficially own the Common Stock beneficially owned by of each of Master Account and Capital Partners (100).

Item 2

(b) Address of Principal Business Office or, If None, Residence; Citizenship:

Each Reporting Person’s principal business address is:

1345 Avenue of the Americas, 42nd Floor, New York, N.Y. 10105.

Item 2

(c) Citizenship:

The information set forth in Item 2(a) hereto is incorporated by reference.

Item 2

(d) Title of Class of Securities:

common stock, par value $0.000041666

Item 2

(e) CUSIP Number:

462260 10 0

Item 3.

If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:


(a)	☐	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)	☐	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)	☐	Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)	☐	Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)	☐	An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);

(h)	☐	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	☐	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).

Item 4.

Ownership

As of the date hereof:

Master Account may be deemed to be the beneficial owner of 17,605,902 shares of Common Stock held for its own account.

Capital Partners (100) may be deemed to be the beneficial owner of 2,391,201 shares of Common Stock held for its own account.

Advisors may be deemed to be the beneficial owner of 19,997,103 shares of Common Stock. This number consists of (A) 17,605,902 shares of Common Stock held for the account of Master Account and (B) 2,391,201 shares of Common Stock held for the account of Capital Partners (100).

MHRC may be deemed to be the beneficial owner of 19,997,103 shares of Common Stock. This number consists of (A) 17,605,902 shares of Common Stock held for the account of Master Account and (B) 2,391,201 shares of Common Stock held for the account of Capital Partners (100).

Fund Management may be deemed to be the beneficial owner of 19,997,103 shares of Common Stock. This number consists of (A) 17,605,902 shares of Common Stock held for the account of Master Account and (B) 2,391,201 shares of Common Stock held for the account of Capital Partners (100).

Holdings may be deemed to be the beneficial owner of 19,997,103 shares of Common Stock. This number consists of (A) 17,605,902 shares of Common Stock held for the account of Master Account and (B) 2,391,201 shares of Common Stock held for the account of Capital Partners (100).

Dr. Rachesky may be deemed to be the beneficial owner of 20,083,951 shares of Common Stock. This number consists of (A) 17,605,902 shares of Common Stock held for the account of Master Account, (B) 2,391,201 shares of Common Stock held for the account of Capital Partners (100) and (C) 86,848 shares of Common Stock held directly by Dr. Rachesky.

The percentages set forth below are calculated based on 255,918,448 shares of Common Stock outstanding as of the date hereof, as reported in the Issuer’s Form 10-Q for the quarter ended September 30, 2023.

Master Account may be deemed to be the beneficial owner of approximately 6.9% of the total number of shares of Common Stock outstanding, calculated in accordance with Rule 13d-3(d)(1)(i) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Capital Partners (100) may be deemed to be the beneficial owner of approximately 0.9% of the total number of shares of Common Stock outstanding, calculated in accordance with Rule 13d-3(d)(1)(i) under the Exchange Act.

Advisors may be deemed to be the beneficial owner of approximately 7.8% of the total number of shares of Common Stock outstanding, calculated in accordance with Rule 13d-3(d)(1)(i) under the Exchange Act.

MHRC may be deemed to be the beneficial owner of approximately 7.8% of the total number of shares of Common Stock outstanding, calculated in accordance with Rule 13d-3(d)(1)(i) under the Exchange Act.

Fund Management may be deemed to be the beneficial owner of approximately 7.8% of the total number of shares of Common Stock outstanding, calculated in accordance with Rule 13d-3(d)(1)(i) under the Exchange Act.

Holdings may be deemed to be the beneficial owner of approximately 7.8% of the total number of shares of Common Stock outstanding, calculated in accordance with Rule 13d-3(d)(1)(i) under the Exchange Act.

Dr. Rachesky may be deemed to be the beneficial owner of approximately 7.8% of the total number of shares of Common Stock outstanding, calculated in accordance with Rule 13d-3(d)(1)(i) under the Exchange Act.

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Not applicable.

Item 9.

Notice of Dissolution of Group

Not applicable.

Item 10.

Certifications

By signing below each signatory certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose of effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 9, 2024


MHR Capital Partners Master Account LP

By:		/s/ Janet Yeung
		Name: Janet Yeung
		Title: Authorized Signatory


MHR ADVISORS LLC

By:		/s/ Janet Yeung
		Name:Janet Yeung
		Title:Authorized Signatory


MHRC LLC

By:		/s/ Janet Yeung
		Name:Janet Yeung
		Title:Authorized Signatory


MHR FUND MANAGEMENT LLC

By:		/s/ Janet Yeung
		Name:Janet Yeung
		Title:Authorized Signatory


MHR HOLDINGS LLC

By:		/s/ Janet Yeung
		Name:Janet Yeung
		Title: Authorized Signatory


MARK H. RACHESKY, M.D.

By:		/s/ Janet Yeung, Attorney in Fact

Get the next $IOVA alert in real time by email

Date	Price Target	Rating	Analyst
10/24/2024	$17.00	Buy	UBS
7/29/2024	$19.00 → $10.00	Overweight → Neutral	Piper Sandler
11/20/2023	$12.00	Buy	Goldman
9/18/2023	$40.00 → $18.00	Overweight	Barclays
5/30/2023	$11.00 → $17.00	Equal Weight → Overweight	Wells Fargo
3/27/2023	$11.00	Equal Weight	Wells Fargo
1/27/2023	$11.00 → $14.00	Neutral → Overweight	Piper Sandler
12/9/2022	$20.00 → $6.00	Buy → Neutral	Goldman

NAMES OF REPORTING PERSONS

MHR Capital Partners Master Account LP

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐ (b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Anguilla, British West Indies